Results 201 to 210 of about 92,991 (335)

S1‐Guideline for diagnosis and therapy of necrobiosis lipoidica

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Necrobiosis lipoidica (NL) is a rare granulomatous skin disease of unknown etiology that occurs frequently in association with diabetes mellitus and other comorbidities. The predilection site is the lower leg, particularly the pretibial areas. The exact pathogenesis remains unclear.
Cornelia Erfurt‐Berge, Regina Renner, Melanie Peckruhn, Jörg Tittelbach, Dorothea Terhorst‐Molawi, Friederike Kauer, Joachim Dissemond   +6 more
wiley   +1 more source

Mold infections in chronic granulomatous disease patients-what comes to the rescue? [PDF]

Bone Marrow Transplant
von Bernuth H, Güngör T.
europepmc   +1 more source

Unexpected cystoscopic images in a patient with Chronic Granulomatous Disease. [PDF]

Urol Case Rep, 2023
Kowalczyk K, Heropolitańska-Pliszka E.
europepmc   +1 more source

Defensive medicine in dermatological practice – Dermatopathology as a mirror of structural challenges

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Defensive medicine refers to diagnostic or therapeutic actions taken primarily to reduce legal liability rather than to benefit the patient. In dermatopathology, defensive practices manifest in frequent immunohistochemical testing, overly cautious report phrasing, and reliance on multidisciplinary tumor boards.
Cornelia Sigrid Lissi Müller, Torsten Hansen, Claus Renzelmann   +2 more
wiley   +1 more source

Consecutive non-Aspergillus Fungal Invasive Infections in Chronic Granulomatous Disease: Data from the French National Reference Center for Primary ImmunoDeficiencies and literature review. [PDF]

J Clin Immunol
Lefevre L, Paccoud O, Neven B, Bougnoux ME, Alligon M, Bruneau J, Fischer A, Moshous D, Bustamante J, Picard C, Poiree S, Guery R, Castelle M, Suarez F, Marcais A, Cheminant M, Rouzaud C, Hermoso DG, Salvator H, Catherinot E, Pilmis B, Luca L, Brion JP, Revest M, Gandemer V, Lelievre L, Alvarez M, Conrad A, Fouyssac F, Gaud C, Blumental S, Blanche S, Lortholary O, Mahlaoui N, Lanternier F.   +34 more
europepmc   +1 more source

Intestinal microbiome and metabolome signatures in patients with chronic granulomatous disease. [PDF]

J Allergy Clin Immunol, 2023
Chandrasekaran P, Han Y, Zerbe CS, Heller T, DeRavin SS, Kreuzberg SA, Marciano BE, Siu Y, Jones DR, Abraham RS, Stephens MC, Tsou AM, Snapper S, Conlan S, Subramanian P, Quinones M, Grou C, Calderon V, Deming C, Leiding JW, Arnold DE, Logan BR, Griffith LM, Petrovic A, Mousallem TI, Kapoor N, Heimall JR, Barnum JL, Kapadia M, Wright N, Rayes A, Chandra S, Broglie LA, Chellapandian D, Deal CL, Grunebaum E, Lim SS, Mallhi K, Marsh RA, Murguia-Favela L, Parikh S, Touzot F, Cowan MJ, Dvorak CC, Haddad E, Kohn DB, Notarangelo LD, Pai SY, Puck JM, Pulsipher MA, Torgerson TR, Kang EM, Malech HL, Segre JA, Bryant CE, Holland SM, Falcone EL.   +56 more
europepmc   +1 more source

Review for "Outcome of chronic granulomatous disease ‐ conventional treatment versus stem cell transplantation"

, 2020

openalex   +1 more source

Harnessing controlled human infection models to accelerate vaccine development for neglected tropical diseases: Lessons from leishmaniasis

European Journal of Clinical Investigation, EarlyView.
Controlled Human Infection Models (CHIMs) offer a powerful approach to accelerate vaccine development for neglected tropical diseases (NTDs). This review highlights scientific and translational advances enabled by CHIMs, with a focus on a novel Leishmania major model.
Vivak Parkash
wiley   +1 more source

Chronic granulomatous disease: lessons in cell biology from monogenic immunodeficiency. [PDF]

Clin Exp Immunol
Mortimer PM, Svetitsky S, Thomas DC.
europepmc   +1 more source

Chronic Granulomatous Disease (CGD): Commonly Associated Pathogens, Diagnosis and Treatment. [PDF]

Microorganisms, 2023
Justiz-Vaillant AA, Williams-Persad AF, Arozarena-Fundora R, Gopaul D, Soodeen S, Asin-Milan O, Thompson R, Unakal C, Akpaka PE.   +8 more
europepmc   +1 more source